Business Today – Builder.ai, once touted as a revolutionary AI startup backed by Microsoft, has collapsed into insolvency after revelations that its flagship no-code development platform was powered not by artificial intelligence—but by 700 human engineers in India.

The company marketed its platform as being driven by an AI assistant named “Natasha,” which could supposedly assemble software applications like Lego bricks. But recent reports and commentary have revealed that behind the scenes, customer requests were manually fulfilled by developers, not machines.

Commenting on the unraveling, Ebern Finance founder Bernhard Engelbrecht described it in a widely circulated post on X: “Customer requests were sent to the Indian office, where 700 Indians wrote code instead of AI,” adding that the end products were often buggy, dysfunctional, and difficult to maintain. “Everything was like real artificial intelligence — except that none of it was.”

India has gotta get their shit together. They’ve been willingly letting themselves get beyond fleeced by the rest of the world (especially America) for decades. Probably centuries. I know there was a time where India had the most robust economy in the world, but somewhere along the line they just bent over and started taking it from the rest of us. I’m sure there’s a million examples of this, but my fiancee works for one of the major insurance companies. It’s an IT-adjacent job. She makes as much money as I do. Nothing crazy, but a solid salary for a 30+ year old American. But about half of the people she works with on a daily basis, people she relies on heavily to complete her job, are working from India. According to her, they’re pretty much as valuable as she is to the company (or maybe slightly less). They put as much time and effort into the job as she does. And I swear to God these guys are making something like $8,500 a year. Just preposterously low wages. I know the USD goes further in India. And I know there are WAY more people over there, so it’s a simple case of supply and demand. But God damn it India. Have some pride. Like, you can’t even get $20k a year for your people working full time jobs for hundred billion dollar corporations? These are people with valuable IT & programming skills who could legitimately make 10x that in the United States. When you look into what some people living in India who work for US companies are actually earning (not to mention the lengths they’ll go to commute-wise to even get to their office), it doesn’t even seem real. 

And the fact that there’s enough money in AI that it’s able to sustain a business comprised of 700 Indian dudes sitting in a call center for 8 years… It’s wild, it’s hilarious, it’s kinda sad, it’s so many things. BuilderAI managed to raise $445M from investors to back their company. Imagine being Sachin Dev Duggal, the found of BuilderAI who sat down to do that math and decided he could pull it off. He saw how valuable AI was. He saw how much money an AI program capable of accomplishing certain tasks was able to rake in. Then he thought to himself, “You know what? For that amount of money, I could afford 700 Indian programmers. I bet they could keep up with that workload.”

picture alliance. Getty Images.

What a legend. What a business model. Builder.AI in particular was marketed to businesses who wanted to build a software or an app without having to code it themselves. Builder.AI would do it for them. People sent their ideas to Builder.AI, and BuilderAI’s “innovative AI software” would spit them out an app. But as long as a warehouse full of Indian dudes were able to effectively get the job done, then who the hell cares how the sausage was made? 

Unfortunately the sausage tasted like shit. To the point that BuilderAI wasn’t able to keep up with costs, and had $37M seized by Viola Credit after defaulting on a $50M loan. 

Commenting on the unraveling, Ebern Finance founder Bernhard Engelbrecht described it in a widely circulated post on X: “Customer requests were sent to the Indian office, where 700 Indians wrote code instead of AI,” adding that the end products were often buggy, dysfunctional, and difficult to maintain. “Everything was like real artificial intelligence — except that none of it was.”

The downfall began when Viola Credit, a lender that extended $50 million to Builder.ai in 2023, seized $37 million after the company defaulted. That move paralyzed the startup’s ability to operate or pay employees. Additional funds held in India remain frozen due to regulatory restrictions, Bloomberg reported.

Once you can no longer pay your employees it’s game over. On top of that, they were misreporting sales. They were using pre-made templates to “create” their apps. Obviously this whole thing was probably never sustainable (unless they were able to raise enough money on the backs of 700 Indian dudes and use it to build a real AI program). Clearly whoever was investing in Builder.AI were in a large part investing in what it could be in the future, as opposed to what it actually was. But maybe there’s a world where if Builder.AI had played their cards right, they could have pulled off. Had they pulled it off, it would have been an incredible John Henry vs The Machine-esque story of mankind triumphing over technology (if John Henry was 700 dudes inside of a trench coach and working for slave wages). 

But in some ways, this is still kind of a win for mankind. There are still things AI isn’t capable of doing. And if someone is able to pull the wool over the eyes of a company like Microsoft because they’re so overeager to eliminate the human workforce entirely in favor of computers, then good for them.

But in other, more real ways, if companies are that overeager to shell out millions and millions of dollars for AI software as opposed to employing hundreds of people… that’s kinda scary. Apparently nobody even bothered to audit Builder.AI, or look into their software, or visit their offices. They just blindly jumped at the opportunity to throw money at the first company who claimed they were capable of building apps without the hassle of hiring human beings.

Maybe, if were lucky, this will be the first domino to fall in the biggest tech-scandal of our lifetimes. Where we all believed AI was taking over the world, but come to learn the likes of OpenAI, Google Gemini, Grok, etc., were just a bunch of Indians in a warehouse the whole time. Wouldn’t that be something. We all thought modern technological advancements were making it so certain tasks could be accomplished in an instant for pennies on the dollar, but in reality, it was the country of India wiling to work for $1.50/hour. We can only hope. 

Advertisement

Blood Vision will be available in all 50 states starting next Tuesday, offering users insights across over 120 biomarkers and integrating with Ultrahuman’s wearable technology

Ultrahuman, known for its wearable health tracking devices, is launching a new platform called Blood Vision today. The product, which will be available across the U.S., is designed to offer a more detailed look into a person’s health by analyzing over 120 biomarkers.

Blood Vision pairs lab-based testing with data from Ultrahuman’s existing wearable, the Ring AIR, giving users the ability to track markers related to cardiovascular, hormonal, metabolic, immune, and aging-related health. The platform is intended to help users monitor their health over time, rather than just through occasional or isolated checkups.

“This approach helps people better understand how their body is functioning and how it’s changing,” said Ultrahuman CEO Mohit Kumar. “By combining blood analysis with continuous data from the Ring, we can give more context to what’s happening inside the body.”

Unlike traditional lab tests, which offer results at a single point in time, Blood Vision is designed to evolve with users. The company says this allows for more personalized insights and a clearer understanding of long-term health trends.

Ultrahuman’s broader goal is to provide tools that make health monitoring more accessible and proactive. With Blood Vision, the company adds a new layer to its platform, which already includes glucose monitoring and home health tracking tools.

Many Americans rely on their Apple Watches or similar devices each day to count their steps, track workouts, and measure how many calories they burn. But are those wearable devices accurate?

University of Mississippi professor Minsoo Kang and doctoral student Ju-Pil Choe are working to answer that question.

Kang, a professor of sports analytics, and Choe reviewed 56 studies that compared the Apple Watch to trusted reference tools in measuring energy burned, heart rate and step counts.

Data from the National Institutes of Health shows that wearable technology has become increasingly popular across all types of users, from elite athletes to the general population, whether active or sedentary. As early as 2015, about 1 in 8 Americans reported using a wearable activity monitor. By 2019, wearable tech had become the top fitness trend, and the market continues to expand.

“If people are using them to make decisions about their workouts or even medical conditions, the data should be accurate,” Choe said. “If the numbers are off, it could lead to confusion, overtraining or even missed health warnings.”

The Ole Miss researchers conducted a meta-analysis to evaluate how the device’s accuracy varied by age, health status, Apple Watch version and type of physical activity.

The findings showed that Apple Watches are generally accurate when measuring heart rate and step counts. The researchers reported mean absolute percent errors, a standard measure of accuracy, of 4.43% for heart rate and 8.17% for step counts, while the error for energy expenditure rose to 27.96%.

This inaccuracy was observed across all types of users and activities tested, including walking, running, cycling and mixed-intensity workouts.

The results indicated that Apple Watches can be a good support tool, such as for tracking basic activity after surgery, but they should not replace clinical tools or medical judgment, Kang said.

“These devices are great for keeping track of habits and staying motivated,” he said. “But do not take every number as 100% truth, especially the calories. Think of it as a helpful guide, not a diagnostic tool. It is useful but not perfect.”

The researchers noted that newer models seem to be more accurate.

“While we cannot say every update is a big leap forward, there is a noticeable trend of gradual improvements over time,” Choe said. “It shows that Apple is refining the technology over time.”

Kang said he hopes this study will help consumers make informed choices about buying and using wearable devices and help manufacturers improve the technology people rely on daily.

“By showing where the weaknesses are, we can help developers get real feedback,” he said. “If they know what needs to be fixed, they can design better sensors or algorithms. “Our findings can guide improvements and help make these devices more useful for both everyday users and health care providers.”

The study is published in the journal Physiological Measurement.

By MATT OTT, AP Business Writer

WASHINGTON (AP) — Meta has cut a 20-year deal to secure nuclear power to help meet surging demand for artificial intelligence and other computing needs at Facebook’s parent company.

The investment with Meta will also expand the output of a Constellation Energy Illinois nuclear plant.

The agreement announced Tuesday is just the latest in a string of tech-nuclear partnerships as the use of AI expands. Financial details of the agreement were not disclosed.

Constellation’s Clinton Clean Energy Center was actually slated to close in 2017 after years of financial losses but was saved by legislation in Illinois establishing a zero-emission credit program to support the plant into 2027. The agreement deal takes effect in June of 2027, when the state’s taxpayer funded zero-emission credit program expires.

With the arrival of Meta, Clinton’s clean energy output will expand by 30 megawatts, preserve 1,100 local jobs and bring in $13.5 million in annual tax revenue, according to the companies. The plant currently powers the equivalent of about 800,000 U.S. homes. George Gross, professor of electrical and computer engineering at the University of Illinois. estimates that 30 additional megawatts would be enough to power a city with about 30,00 residents for one year.

“Securing clean, reliable energy is necessary to continue advancing our AI ambitions,” said Urvi Parekh, Meta’s head of global energy.

BILLERICA, Mass.–(BUSINESS WIRE)–Jun 3, 2025–

Bruker Corporation (NASDAQ: BRKR) today announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the 73rd American Society for Mass Spectrometry (ASMS) Conference, taking place June 1–5, 2025, in Baltimore, Maryland. These developments reflect Bruker’s continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603080303/en/

RECIPE kits for clinical laboratories

Bruker Applied MS will showcase two significant innovations: the integration of RECIPE’s ClinMass ® and ClinDART ® assay kits with Bruker’s EVOQ ® DART-TQ⁺ system for TDM and DoA applications, and the launch of the new timsMetabo™ platform for advanced small molecule analysis. These developments support Bruker’s goal of delivering practical, high-performance solutions for routine analytical challenges.

Bruker’s recent majority investment in RECIPE, a renowned manufacturer of diagnostic assays for small molecule analysis used with triple quadrupole mass spectrometers, marks an important step in expanding its capabilities in TDM and DoA analysis. Since the acquisition, Bruker and RECIPE have collaborated to verify the IVDR certified ClinMASS ® kits for use on the EVOQ DART-TQ⁺ system, initially targeting high-priority compound classes. They are not US-FDA approved, but single compounds as controls and calibrators may be a basis in LDT approaches. In parallel, the companies are preparing the launch of RECIPE’s ClinDART ® kits, which are designed as high-throughput, chromatography-free assays for the EVOQ DART-TQ⁺ system. These kits enable rapid, cost-efficient analysis with highly reduced solvent consumption, ease of use and increased lab productivity. All ClinDART ® protocols are currently designated for Research Use Only (RUO).

Meanwhile, the newly introduced timsMetabo™ platform represents a leap forward in small molecule analysis. Built on Bruker’s proprietary trapped ion mobility spectrometry (TIMS) and enhanced with Mobility Range Enhancement (MoRE) and the Athena Ion Processor (AIP), timsMetabo™ delivers high sensitivity and selectivity for PFAS detection. In early studies, timsMetabo™ identified 40% more low-mass molecules in water samples compared to previous-generation systems. This innovation supports both regulatory compliance and proactive environmental monitoring, with promising applications in toxicology and forensic science.

“The integration of RECIPE’s assay expertise with Bruker’s DART triple quad instrumentation is a significant advancement for therapeutic drug monitoring,” said Dr. Gernot Wolfram, Managing Director of RECIPE. “It represents a promising concept with the potential to enable laboratories to adopt high-throughput, chromatography-free workflows that are efficient, robust, and more sustainable. These could dramatically enhance overall lab productivity and make mass spectrometry more accessible and impactful in routine clinical settings.”

“ASMS 2025 marks an important milestone for Bruker Applied MS,” said Jeffrey Zonderman, Senior Vice President of Bruker Applied Mass Spectrometry. “With the launch of timsMetabo™ and the strategic integration of RECIPE, we are not only expanding our technology portfolio but also redefining what’s possible in applied markets. These innovations reflect our commitment to solving real-world analytical challenges in TDM and environmental analysis.”

Looking ahead, Bruker Applied MS will continue to develop solutions for PFAS, forensic toxicology, and therapeutic drug monitoring. The timsMetabo™ platform is expected to support future applications involving low-mass drug metabolites and emerging contaminants, while RECIPE’s assay pipeline will further enhance Bruker’s applied market offerings.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20250603080303/en/

CONTACT: Investor Contact:

Joe Kostka

Director, Investor Relations

Bruker Corporation

T: +1 (978) 313-5800

E:Investor.Relations@bruker.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: SOFTWARE PROFESSIONAL SERVICES PHARMACEUTICAL TECHNOLOGY MEDICAL DEVICES ENVIRONMENT DATA ANALYTICS CLINICAL TRIALS SCIENCE BIOTECHNOLOGY FDA HEALTH OTHER SCIENCE

SOURCE: Bruker Corporation

Copyright Business Wire 2025.

PUB: 06/03/2025 11:00 AM/DISC: 06/03/2025 11:01 AM

http://www.businesswire.com/news/home/20250603080303/en